Vasculitis Treatment Market By Drug Class, By Disease Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

Description

List of Tables

Vasculitis causes inflammation of the blood vessels. Blood vessel walls may thicken as a result of the inflammation, reducing the diameter of the vessel's passage. Vasculitis is the inflammation of capillaries, veins, and arteries. The illness has no age restrictions and can affect both sexes equally. There are many different types of vasculitis, and their scientific characteristics might differ greatly in terms of severity, symptoms, and disease duration. The type of vasculitis differs depending on which blood vessels are affected.

The major factors that drive the growth of the vasculitis treatment market is increase in geriatric population, and rise in incidence of chronic diseases. In addition, shift toward the adoption rate of biologics and its development is a key trend of the market which is expected to fuel the market growth during the forecast period.

Many key market players are investing in R&D activities and launching new biologics products for the treatment of vasculitis. Various inorganic strategies, such as acquisition, are adopted by the key market players for expansion of the vasculitis treatment market. For instance, in August 2022 Amgen and ChemoCentryx, a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx.

In addition, the global demand for vasculitis treatment has increased as a result of the rise in the development of drugs and R&D activities related to them, which is a major driving force behind the growth of the vasculitis treatment market. However, side effects associated with usage of corticosteroids are expected to hinder the growth of the market. Conversely, rise in R&D activities for drug discovery and development to suffice the consumer demands in developing countries is expected to provide a great opportunity for the investors to invest in the market.

The global vasculitis treatment market is segmented on the basis of drug class, disease type, distribution channel, and region. On the basis of drug class, the market is categorized into biologics, corticosteroids, and immunosuppressants. As per disease type, it is divided into small & medium vessel vasculitis, and large vessel vasculitis. Small & medium vessel vasculitis is further bifurcated as ANCA associated vasculitis and others. Depending on distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major players profiled in the report are AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, InflaRx NV, Novartis AG, Pfizer Inc., Staidson Biopharma Inc., and Teva Pharmaceuticals Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vasculitis treatment market analysis from 2021 to 2031 to identify the prevailing vasculitis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vasculitis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vasculitis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

Hospital pharmacies
Drug store and retail pharmacies
Online Pharmacies

By Drug Class

Corticosteroids and immunosuppressants
Biologics

By Disease Type

Small and medium vessel vasculitis
- Type
- ANCA associated vasculitis
- Others
Large vessel vasculitis

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Amneal Pharmaceuticals, Inc.
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd
- Glaxosmithkline plc
- Pfizer Inc.
- InflaRx N.V
- Novartis AG
- ChemoCentryx
- AbbVie
- Teva Pharmaceutical Industries Ltd.

Product Code: A03183

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape

CHAPTER 4: VASCULITIS TREATMENT MARKET, BY DRUG CLASS

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Biologics
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Corticosteroids and immunosuppressants
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country

CHAPTER 5: VASCULITIS TREATMENT MARKET, BY DISEASE TYPE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Small and medium vessel vasculitis
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Small and medium vessel vasculitis Vasculitis Treatment Market by Type
  - 5.2.4.1 ANCA associated vasculitis Market size and forecast, by region
  - 5.2.4.2 Others Market size and forecast, by region
5.3 Large vessel vasculitis
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Drug store and retail pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country

CHAPTER 7: VASCULITIS TREATMENT MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
- 7.2.3 North America Market size and forecast, by Disease Type
  - 7.2.3.1 North America Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Drug Class
  - 7.2.5.1.2 Market size and forecast, by Disease Type
  - 7.2.5.1.3 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Drug Class
  - 7.2.5.2.2 Market size and forecast, by Disease Type
  - 7.2.5.2.3 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Drug Class
  - 7.2.5.3.2 Market size and forecast, by Disease Type
  - 7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
- 7.3.3 Europe Market size and forecast, by Disease Type
  - 7.3.3.1 Europe Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Drug Class
  - 7.3.5.1.2 Market size and forecast, by Disease Type
  - 7.3.5.1.3 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Drug Class
  - 7.3.5.2.2 Market size and forecast, by Disease Type
  - 7.3.5.2.3 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Market size and forecast, by Drug Class
  - 7.3.5.3.2 Market size and forecast, by Disease Type
  - 7.3.5.3.3 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Drug Class
  - 7.3.5.4.2 Market size and forecast, by Disease Type
  - 7.3.5.4.3 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Drug Class
  - 7.3.5.5.2 Market size and forecast, by Disease Type
  - 7.3.5.5.3 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Drug Class
  - 7.3.5.6.2 Market size and forecast, by Disease Type
  - 7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.3 Asia-Pacific Market size and forecast, by Disease Type
  - 7.4.3.1 Asia-Pacific Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Market size and forecast, by Drug Class
  - 7.4.5.1.2 Market size and forecast, by Disease Type
  - 7.4.5.1.3 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Market size and forecast, by Drug Class
  - 7.4.5.2.2 Market size and forecast, by Disease Type
  - 7.4.5.2.3 Market size and forecast, by Distribution Channel
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Drug Class
  - 7.4.5.3.2 Market size and forecast, by Disease Type
  - 7.4.5.3.3 Market size and forecast, by Distribution Channel
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Drug Class
  - 7.4.5.4.2 Market size and forecast, by Disease Type
  - 7.4.5.4.3 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Drug Class
  - 7.4.5.5.2 Market size and forecast, by Disease Type
  - 7.4.5.5.3 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Drug Class
  - 7.4.5.6.2 Market size and forecast, by Disease Type
  - 7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
- 7.5.3 LAMEA Market size and forecast, by Disease Type
  - 7.5.3.1 LAMEA Small and medium vessel vasculitis Vasculitis Treatment Market by Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Drug Class
  - 7.5.5.1.2 Market size and forecast, by Disease Type
  - 7.5.5.1.3 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Drug Class
  - 7.5.5.2.2 Market size and forecast, by Disease Type
  - 7.5.5.2.3 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Drug Class
  - 7.5.5.3.2 Market size and forecast, by Disease Type
  - 7.5.5.3.3 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Drug Class
  - 7.5.5.4.2 Market size and forecast, by Disease Type
  - 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Amneal Pharmaceuticals, Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 AstraZeneca plc
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 F. Hoffmann-La Roche Ltd
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Glaxosmithkline plc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Pfizer Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 InflaRx N.V
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Novartis AG
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 ChemoCentryx
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 AbbVie
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Industries Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments